Eribulin
Other Antineoplastic Agents
Sold as Mevlyq · Halaven
- Drug class
- Other Antineoplastic Agents
- Availability
- Prescription only
- Routes
- Intravenous
- Markets covered
- 4
- Products on record
- 19
Overview
Plain-language summary, compiled from the cited regulatory records
Eribulin is a medication classified as an "other antineoplastic agent" [1]. It functions as a microtubule inhibitor [1].
Eribulin is approved for treating certain types of cancer. It is indicated for patients with metastatic breast cancer who have previously undergone at least two chemotherapy regimens for their metastatic disease. The prior treatment must have included an anthracycline and a taxane, administered either in the adjuvant or metastatic setting [1].
Additionally, eribulin is approved for patients with unresectable or metastatic liposarcoma who have previously received an anthracycline-containing regimen [1].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 12 | May 15, 2026 |
| EU European Union | EMA | 3 | February 24, 2026 |
| CA Canada | Health Canada | 3 | February 16, 2026 |
| US United States | FDA | 1 | January 20, 2026 |
GBUnited Kingdom· MHRA
12 products
Uses
1). Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments. 1).
How to take
EUEuropean Union· EMA
3 products
Uses
1). Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting unless patients were not suitable for these treatments. 1).
How to take
CACanada· Health Canada
3 products
Uses
AND CLINICAL USE ................................................................... 3 CONTRAINDICATIONS ........................................................................................ 3 WARNINGS AND PRECAUTIONS.......................................................................
4 ADVERSE REACTIONS ........................................................................................ 7 DRUG INTERACTIONS ...................................................................................... 13 DOSAGE AND ADMINISTRATION ..................................................................
14 OVERDOSAGE ..................................................................................................... 16 ACTION AND CLINICAL PHARMACOLOGY ................................................. 17 STORAGE AND STABILITY ..............................................................................
19 SPECIAL HANDLING INSTRUCTIONS ............................................................ 19 DOSAGE FORMS, COMPOSITION AND PACKAGING .................................. 19 PART II: SCIENTIFIC INFORMATION ....................................................................
USUnited States· FDA
1 product
Uses
1 INDICATIONS AND USAGE Eribulin mesylate injection is a microtubule inhibitor indicated for the treatment of patients with: Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease.
Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. 1 ) Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. 1 Metastatic Breast Cancer Eribulin mesylate injection is indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease.
1 )]. 2 )] .
How to take
Drug interactions
Known interactions involving Eribulin. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 329. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL115870143 · revised February 20, 2026
- [2]European Medicines Agency · EMEA/H/C/006191 · revised February 24, 2026
- [3]Health Canada (DPD) · 02560399 · revised November 17, 2025
- [4]FDA DailyMed · 1038e984-3bf7-5b… · revised January 20, 2026 [PDF]
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.